SEQ ID NO:8 shows the amino acid sequence of the ER-interacting domain of AIB1.

SEQ ID NO:9 shows the nucleic acid sequence of pCIP, the mouse ortholog of AIB1 and the amino acid sequence for this gene.

SEQ ID NO:10 shows the nucleic acid sequence of the forward primer AIB1/mESTF1 used to screen mouse BAC.

SEQ ID NO:11 shows the nucleic acid sequence of the reverse primer AIB1/mESTF1 used to screen mouse BAC.

SEQ ID NO:12 shows the amino acid sequence of pCIP, the mouse ortholog of AIB1.--

On page 5, line 10, please delete the paragraph (the section title) which reads "FIGURES," and insert therefor --BRIEF DESCRIPTION OF THE DRAWINGS--.

Please delete the paragraph on page 5, lines 11-14 and insert therefor:

--Fig. 1A is a diagram of an amino acid sequence of full length AIB1 (SEQ ID NO:4) in which residues highlighted in black are identical in AIB1, TIF2, and SRC1. Residues identical with TIF2 (GenBank Accession No. X97674) or SRC-1 (GenBank Accession No. U59302) are highlighted in grey or boxed, respectively.--

Please delete the paragraph on page 5, lines 33-37, and insert therefor:

--~~Fig. 5 is~~ Fig. 5A and Fig. 5B are a table showing the introns and exons of the mouse AIB1 gene (pCIP) (SEQ ID NO:9). The "Exon" column refers to the number of the exon; "cDNA bp 5'-exon" refers to the nucleotide position in the mouse cDNA sequence for the 5' exon; "cDNA bp 3' exon" refers to the last few nucleotides of the 3' position of the intron. "Exon sequence" refers to the exon itself. "5' intron" refers to the adjacent intron reading from the exon into the splice donor elinucleotides (usually GT).

Please delete the paragraph on page 6, lines 1-5, and insert therefor:

--Fig. 6A and Fig. 6B are a table showing the introns and exons of the human AIB1 gene (SEQ ID NO:1). The "Exon" column refers to the number of the exon; "cDNA bp 5'-exon" refers to the nucleotide position in the mouse cDNA sequence for the 5' exon; "cDNA bp 3' exon" refers to the last few nucleotides of the 3' position of the intron. "Exon sequence" refers to the exon itself.

cont D10

"5' intron" refers to the adjacent intron reading from the exon into the splice donor elinucleotides (usually GT).--

REMARKS

Claims 12, 13, 18-21, and 55-65 are amended herein. New claims 66-69 are added. Support for the amendments to claim 12 can be found in the specification on page 6, lines 21-28, and on page 8, lines 10-36. Support for the amendment of claim 13 can be found in the specification on page 4, line 33, and on page 7, lines 8-10. Claim 18 is amended to correct form. Support for the amendment of claim 19 can be found in the specification on page 7, lines 2-6. Support for the amendment of claim 20 can be found in the specification on page 7, lines 6-9. Support for the amendment of claim 21 can be found in the specification on page 6, lines 21-28, and on page 8, lines 10-36. Support for the amendment of claim 55 can be found in the specification on page 6, lines 21-28, and on page 8, lines 10-36. Claims 56-60 and 63-64 are amended to correct form. Support for the amendment of claims 61 and 62 can be found in the specification on page 7, line 32. Support for the amendment of claim 65 can be found in the specification on page 6, line 21 and on page 7, line 28. Support for new claims 66-67 can be found in the specification on page 8, lines 1-8. Support for new claims 68-69 can be found in the specification on page 7, line 32.

No new matter is added. Reconsideration of the subject application is respectfully requested.

Restriction Requirement

The restriction requirement found a lack of unity of invention, based on the availability of Guan et al., Cancer Research 56:3446-3450, (August 1, 1996) as prior art. Applicants submit herewith a signed declaration under 37 C.F.R. § 1.132 of Jeffrey Trent and Paul Metlzer, documenting that Paul Meltzer and Jeffrey Trent, the co-applicants in the present application, are the sole inventors of the subject matter claimed herein. Although the Guan et al. reference contains additional authors, the declaration states that these other individuals did not make an inventive contribution to the claimed invention. As discussed in the Office action, this declaration is sufficient to rejoin the claims of Group I (drawn to polynucleotides) with the claims of Group II (drawn to polypeptides) and Group IV (method of identifying a candidate compound). Examination of claims 12-13 and claims 14-21 and 26-27 is respectfully requested.

60